ImmunityBio's Shares Jump On Encouraging Data From Pancreatic Cancer Immunotherapy Trial

ImmunityBio Inc IBRX has revealed early results from its Phase 2 metastatic pancreatic cancer trial (QUILT 88), showing that patients' overall survival rate doubled compared to the historical survival rate. 

  • Phase 2 evaluates the comparative efficacy and overall safety of standard-of-care chemotherapy versus low-dose chemotherapy combined with PD-L1 t-haNK, Anktiva (N-803), and aldoxorubicin in locally advanced or metastatic pancreatic cancer.
  • The combination immunotherapy also showed treatment-related serious adverse events were uncommon (8%), and no treatment-related deaths were reported. 
  • Related: ImmunityBio Meets Endpoint In Second Indication Cohort In Bladder Cancer Trial.
  • To date, 27% of third-line or greater patients (17/63) remain on study. The median overall survival in this highly advanced group of patients, who failed two to six prior lines of treatment, is 5.8 months exceeding the approximately three-month historical median overall survival. 
  • Of the 63 patients, 30 (48%) had progressed after two prior lines of therapy. The median overall survival in this group was 6.3 months, more than doubling the overall historical survival.
  • Price Action: IBRX shares are up 8.24% at $6.70 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsPancreatic Cancerwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!